BioSpace News Archive

Singapore-based ASLAN slashed 30 percent of its staff following a recent mid-stage failure, and California-based Aduro has cut 37 percent of employees.

New RESCUE Trial Data Presented in Blunt Thoracic Aortic Injury

As the trial against John Kapoor and other former executives at Insys Therapeutics continues, more sordid details of an aggressive campaign to boost sales of the company’s fentanyl-based sublingual spray for cancer pain are being brought to light.

For 2018, Pfizer reported revenues of $53.6 billion, which was 2 percent operational growth. The fourth quarter brought in $14 billion, which was 5 percent operational growth.

It’s no secret that the global biopharma and life sciences industry is large. Sometimes the immense size of the industry can lead fascinating news tidbits to fall through the cracks, particularly those from smaller companies scattered across the globe. This week BioSpace will launch a new roundup of news from companies across the globe.

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced positive results from the MicroStat Phase 3 MIST-1 study.

Article provides full data set of pivotal clinical trial showing that HEMOBLAST Bellows is clinically and statistically superior to control at achieving hemostasis

Phage therapy could offer an alternative treatment method in the fight against antimicrobial resistance

Company Is Committed to Leading Evidence Generation Across the Lung Cancer Care Continuum

Series celebrates seventh consecutive year providing a benchmark for payment technology & adoption in industries including ARM, Financial Services and Healthcare